Home Medizin Neue RSV-Antikörperbehandlung bei Säuglingen zeigt starke Ergebnisse

Neue RSV-Antikörperbehandlung bei Säuglingen zeigt starke Ergebnisse

von NFI Redaktion

The new RSV antibody treatment for babies has proven to be extremely effective in its first season, according to initial data from four children’s hospitals.

According to a new estimate published by the CDC, babies who received the new preventive RSV treatment shortly after birth had a 90% lower chance of developing severe respiratory illness, which can be potentially deadly. This data marks the first real-world assessment of Beyfortus (the generic name is Nirsevimab), which was approved by the FDA last July.

RSV is a seasonal illness that affects more people in the fall and winter, especially infants and older adults. While healthy adults usually experience mild symptoms, infants are particularly vulnerable to bronchiolitis, which leads to wheezing and coughing due to inflammation of the airways and lungs. Hospitalized infants may require fluids and medical devices to help with breathing.

RSV peaked this season from November to January, with the CDC reporting over 10,000 monthly diagnoses.

The new CDC analysis was conducted on approximately 700 babies admitted to the hospital from October to the end of February due to severe breathing problems. Of these babies, 407 were diagnosed with RSV and 292 tested negative. The researchers found that only 1% of babies diagnosed with RSV in the study had received Beyfortus, while the rest of the RSV-positive babies had not.

Of the babies hospitalized for other severe breathing problems, 18% had received Beyfortus. Overall, only 59 out of nearly 700 babies in the study received Beyfortus, possibly due to limited availability of the medication in its first season. The authors noted that babies in the study who received Beyfortus tended to have higher-risk conditions.

The exact number of babies nationwide who received Beyfortus in this first availability season is unclear, but a CDC survey in January found that 4 in 10 parents reported their babies under 8 months had received the treatment. The Wall Street Journal recently reported that a shortage last fall was due to underestimated demand and production plans that were set before the CDC recommended Beyfortus for all infants under 8 months whose mothers had not received maternal vaccinations to protect infants from RSV.

Both the antibody treatment for infants and the maternal vaccine have been shown in clinical trials to be approximately 80% effective in preventing severe RSV-related illnesses.

The authors of the latest CDC report concluded that „… this early estimate supports the current recommendation of Nirsevimab for preventing severe RSV illnesses in infants. Infants should be protected through maternal RSV vaccination or administration of Nirsevimab to the infant.“

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.